Introduction Malignant pleural disease (MPD) arises from direct extension of an adjacent tumour, pleural metastases of distant tumours or a primary pleural neoplasm, most commonly malignant pleural mesothelioma (MPM) [1]. MPD can manifest as solid disease and/or malignant pleural effusion (MPE), both associated with high morbidity and mortality [2]. MPE, defined by the accumulation of pleural fluid accompanied by malignant cells in the pleural space, can complicate any cancer [3, 4].
